Ontology highlight
ABSTRACT: Background
Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and adverse events.Objective
To identify risk factors for ADAb in the early phase of infliximab treatment.Methods
Patients (n = 410) with immune-mediated inflammatory diseases who initiated infliximab treatment were included in the 38-week Norwegian Drug Monitoring Trial (NOR-DRUM) A and randomised 1:1 to therapeutic drug monitoring (TDM) or standard therapy. Serum levels of infliximab and ADAb were measured at each infusion. Possible risk factors for ADAb formation were assessed using logistic regression, adjusting for potential confounders.Results
ADAb were detected in 78 (19%) pa
SUBMITTER: Brun MK
PROVIDER: S-EPMC9545769 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature